Express News | HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target
Viridian Therapeutics Analyst Ratings
Sector Update: Health Care
Sector Update: Health Care Stocks Gain in Afternoon Trading
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
US FDA Animal Testing De-Emphasis May Boost Biotech Innovation, RBC Says
Viridian Therapeutics Appoints Jeff Ajer to Its Board of Directors
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $41
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)
Express News | Viridian Therapeutics Inc - Enters $300 Million Sale Agreement With Jefferies
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
Viridian Therapeutics | 10-K: FY2024 Annual Report
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $34
RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains Outperform - Speculative Risk Rating
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $27 to $46
Viridian Therapeutics Positioned for Market Leadership With Strategic Advancements and Competitive Edge
Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating
Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)
Viridian Therapeutics | 8-K: Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results